Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Nov 14:40:80.
doi: 10.1186/s13052-014-0080-8.

Severe congenital neutropenia due to G6PC3 deficiency: early and delayed phenotype in two patients with two novel mutations

Affiliations
Case Reports

Severe congenital neutropenia due to G6PC3 deficiency: early and delayed phenotype in two patients with two novel mutations

Lucia Dora Notarangelo et al. Ital J Pediatr. .

Abstract

Severe Congenital Neutropenia type 4 (SCN4, OMIM 612541) is a rare autosomal recessive disease due to mutations in the G6PC3 gene. The phenotype comprises neutropenia of variable severity and other anomalies including congenital heart defects, prominent superficial veins, uro-genital anomalies, facial dysmorphism, growth and developmental delay and intermittent thrombocytopenia. In some patients, SCN represents the only manifestation of the disease. Variable findings have been reported at bone marrow examination ranging from a maturation arrest at the myelocyte/promyelocyte stage (either in a hypocellular or hypercellular context) to myelokathexis. Here we report two patients harbouring two novel mutations in the G6PC3 gene, including the first Italian patient even described. Both the patients share profound neutropenia with severe infections early in life; in one case non-hematopoietic stigmata of the syndrome, including evident facial dysmorphism and vascular anomalies, appeared gradually over time, prominently in the second decade. Therefore, G6PC3 defects should be considered in any case of congenital, unexplained neutropenia regardless of the clinical phenotype. Both patients are on G-CSF treatment with no evidence of malignant evolution. Even if G6PC3 deficiency seems not to have a propensity towards malignancy, a careful evaluation is warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Segregation analysis of the mutations identified in patient 1 (A) and patient 2 (B).

References

    1. Donadieu J, Fenneteau O, Beaupain B, Mahlaoui N, Bellanné Chantelot C: Congenital neutropenia: diagnosis, molecular bases and patient management.Orphanet J Rare Dis 2011, 6:26. - PMC - PubMed
    1. Botzug K, Klein C. Genetic etiologies of severe congenital neutropenia. Curr Opin Pediatr. 2011;23(1):21–26. doi: 10.1097/MOP.0b013e32834262f8. - DOI - PubMed
    1. Ghosh A, Shieh JJ, Pan CJ, Yang Chou J. Histidine 167 Is the Phospate Acceptor in Glucose-6-phosphate-β Forming a Phosphohistidine Enzyme Intermediate during Catalysis. J Biol Chem. 2004;279:12479–12483. doi: 10.1074/jbc.M313271200. - DOI - PubMed
    1. Banka S, Newman WG: A clinical and molecular review of ubiquitous glucose-6 phosphatase deficiency caused by G6PC3 mutations.Orphanet J Rare Dis 2013, 8:84. - PMC - PubMed
    1. Bradley NS, Evans C, Ali A, Ancliff PJ, Hayee B, Segal AW, Hall G, Kaya Z, Shakoori AR, Linch DC, Gale RE. Phenotypic heterogeneity and evidence of a founder effect associated with G6PC3 mutations in patients with severe congenital neutropenia. Br J Haematol. 2012;158:138–152. doi: 10.1111/j.1365-2141.2012.09092.x. - DOI - PMC - PubMed

Publication types

Supplementary concepts